A Study of ASKG315 in Patients With Advanced Solid Tumors.

Advanced Solid Tumors Clinical Trial

Official title:

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASKG315 as a Single Agent in Patients With Locally Advanced or Metastatic Malignant Solid Tumors.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05554666
• Other study ID #: ASKG315-001
• Status: Recruiting
• Phase: Phase 1
• Start date: October 15, 2022
• Est. completion date: October 31, 2024

Study information

• Verified date: September 2022
• Source: AskGene Pharma, Inc.
• Contact: Jing Chen, MD
• Phone: 086-15895835292
• Email: chenjing[@]ask-pharm.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a Phase 1, open-label, multicenter, dose escalation study to evaluate the safety, tolerability, PK and PD of ASKG315 as a single agent in patients with advanced solid tumors.

Description:

Each part of the study consists of 3 periods: screening (up to 28 days), treatment and follow-up. After an initial screening period, ASKG315 will be administered once every 3 weeks by intravenous (IV) infusion. The Part 1 dose escalation consists of 6 planned escalation cohorts, with a starting dose of 3 mg.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 56
• Est. completion date: October 31, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Male or female = 18 years of age.

2. Histologically or cytologically confirmed advanced malignant solid tumor that is refractory to or intolerant of all standard therapy or for which no standard therapy is available.

3. Measurable disease, per RECIST v1.1.

4. ECOG Performance Status of = 2.

5. Life expectancy of =3 months, in the opinion of the Investigator.

6. Adequate organ function defined.

7. Fertile patients must be willing to use effective contraceptive measures (hormonal or barrier methods or abstinence, etc.) during the trial and at least 90 days after the last dose;negative serum pregnancy test for female patients within 7 days prior to the first dose of the study drug or documentation of lack of childbearing potential.

8. Voluntarily enrolled and signed the informed consent form, followed the experimental treatment plan and visit arrangement.

Exclusion Criteria:

1. Received chemotherapy within 3 weeks prior to Cycle 1 Day 1; received radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, or any other anti-tumor treatments within 4 weeks prior to Cycle 1 Day 1.

2. Received any other investigational drug for treatment that is not commercially available within 4 weeks prior to Cycle 1 Day 1.

3. Had major organ surgery or significant trauma within 4 weeks prior to C1D1 or planning elective surgery during the study period.

4. Received systemic glucocorticoid or other immunosuppressant treatment within 2 weeks prior to C1D1.

5. Received immunomodulatory drugs, including but not limited to thymosin and interferon, within 2 weeks prior to C1D1.

6. Received a live attenuated vaccine within 4 weeks prior to C1D1.

7. Received IL-2 or IL-15 therapy within 4 weeks prior to C1D1.

8. History of hematologic stem cell transplant or solid organ transplant.

9. Adverse reactions to previous antitumor therapy have not recovered to CTCAE 5.0 grade = 1.

10. Cerebral parenchymal metastasis or meningeal metastasis with clinical symptoms.

11. Serious infection requiring intravenous infusion or hospitalization, or active viral infection.

12. Current clinically significant interstitial lung disease.

13. History of serious cardiovascular or cerebrovascular diseases.

14. Active or recurrent autoimmune diseases.

15. History of Grade = 3 Immune-Related Adverse Events (irAE) or Grade = 2 immunotherapy-associated myocarditis associated.

16. Other malignancies within 5 years.

17. Bleeding symptoms of CTCAE 5.0 grade =3 within 4 weeks prior to C1D1.

18. Symptomatic with uncontrolled ascites or pleural effusion.

19. Hyperglycemia that cannot be stably controlled.

20. History of a grade = 3 allergic reaction to protein drugs.

21. Known to have alcohol or drug dependence.

22. Severe mental disorder or poor compliance.

23. Pregnant or nursing women

24. Subjects should be excluded in the opinion of investigators.

Related Conditions & MeSH terms

• Advanced Solid Tumors
• Neoplasms

Intervention

Biological:
• ASKG315
Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.

Locations

Country	Name	City	State
China	Harbin Medical University Cancer Hospital	Harbin	Heilongjiang
China	Shandong cancer hospital	Jinan	Shandong
China	the First Affiliated Hospital of Nanchang University	Nanchang	Jiangxi
China	Shanghai East Hospital	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
AskGene Pharma, Inc.	Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limiting toxicities (DLTs)	To evaluate the safery of ASKG315 in subjects.	21days
Primary	Adverse events(AEs)	To evaluate the safery of ASKG315 in subjects.	21days
Secondary	Maximum plasma concentration (Cmax)	To evaluate the systemic pharmacokinetics of ASKG315 in subjects.	21days
Secondary	Area under the concentration time curve (AUC)	To evaluate the systemic pharmacokinetics of ASKG315 in subjects.	21days
Secondary	Cytokine	Increase in circulating cytokine levels.	21days
Secondary	Immunocyte	Changes in immunocyte levels by flow cytometry.	21days